Sarepta Therapeutics Q4 2024 Adj. EPS $1.90, Inline, Sales $658.412M Beat $627.582M Estimate

Benzinga
02-27

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $1.90 per share which met the analyst consensus estimate. This is a 131.71 percent increase over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $658.412 million which beat the analyst consensus estimate of $627.582 million by 4.91 percent. This is a 65.94 percent increase over sales of $396.781 million the same period last year.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10